Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 baxdrostat plus dapagliflozin versus dapagliflozin alone in chronic kidney disease with hypertension
CTR20250330Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of baxdrostat, dapagliflozin in chronic kidney disease (CKD), hypertension (HTN), sponsored by AstraZeneca. Started Mar 2025; status: active.
02
Drugs
baxdrostatdapagliflozin
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on CTR20250330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250330.